There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report) with bullish sentiments.
Biogen (BIIB)
Needham analyst Ami Fadia maintained a Buy rating on Biogen today and set a price target of $294.00. The company’s shares closed last Tuesday at $193.18, close to its 52-week low of $189.44.
According to TipRanks.com, Fadia is a 3-star analyst with an average return of
Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $285.59, which is a 47.7% upside from current levels. In a report issued on April 9, Morgan Stanley also maintained a Buy rating on the stock with a $339.00 price target.
See the top stocks recommended by analysts >>
BioMarin Pharmaceutical (BMRN)
In a report released today, Akash Tewari from Jefferies assigned a Buy rating to BioMarin Pharmaceutical, with a price target of $128.00. The company’s shares closed last Tuesday at $92.06.
According to TipRanks.com, Tewari is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioMarin Pharmaceutical with a $111.24 average price target, a 23.6% upside from current levels. In a report issued on April 15, Truist Financial also initiated coverage with a Buy rating on the stock with a $140.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIIB:
